- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04110834
Clinical Assessment of Itraconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel
Clinical Evaluation of a Formulated Nanoemulsion for Topical Application
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The clinical work has been carried out in accordance with The Code of Ethics of the World Medical Association for experiments involving humans. The study was conducted on 30 patients (10 to 60 years old) with tinea versicolor attending the dermatology department outpatient clinic of Minia University Hospital. Local institutional review board approval was obtained for this study (ethical approval number is 24/18). Pregnant or lactating females and Immunocompromized patients. The patients were then divided into 3 groups, placebo group, group A and group B, consisting of 10 patients each. The placebo group received unmedicated formulation, Group A received the medicated formulation once daily and group B were treated twice daily. An informed consent has been obtained from all patients enrolled in the study for photography and treatment. History and general local examination were performed for all patients.The patients were clinically examined under normal light and using wood's lamp and cello-tape test was performed to confirm infection after determining the type of infection and in some cases scrapes were taken to detect infection in clinically indefinite cases and stained using potassium hydroxide 20% then examined for presence of fungal elements. Treatment was performed by applying the gel once or twice daily until full recovery was achieved with follow up once a week to reassess the condition. The clinical improvement of the patients, patient satisfaction and length of treatment were assessed. It was rated by both patient and physician as excellent, good, fair or poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectations, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with some improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.High resolution digital photographs were taken for lesions of all patients using identical camera folder setting before starting treatment, on each follow up visit and after complete recovery. Clinical improvement was evaluated by physicians. The criteria for evaluations using a quartile grading scale were: 0=no improvement. 1=mild (percent improvement, less than 25%), 2=moderate (percent improvement 25-49%), 3=good (percent improvement 50-74%), 4=excellent (percent improvement equal to or more than 75%). In addition, a patient satisfaction score was rated using the following scale, A. satisfied, B.
somewhat satisfied, C. not satisfied. The acceptability of the tested formulations was assessed using the chi-square test, P ≤ 0.05 was considered statistically significant. All the results were presented as the mean ± standard deviation (SD).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minia
-
Minya, Minia, Egypt, 61519
- Minia University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Tinea Versicolor infection
Exclusion Criteria:
- concomitant treatment with other medications for the same condition being studied, TVC.
- pregnancy
- lactation
- immunocompromised patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: once daily application
the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case.
if complete cure is achieved, stop application.
if not, repeat for one more week and then reassess.
|
itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
|
EXPERIMENTAL: twice daily application
the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case.
if complete cure is achieved, stop application.
if not, repeat for one more week and then reassess.
|
itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
|
PLACEBO_COMPARATOR: placebo
the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
|
the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
complete cure
Time Frame: 1-4 weeks
|
1-4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Dermatomycoses
- Tinea Versicolor
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
- Hydroxyitraconazole
Other Study ID Numbers
- ITZSaraSNEDDS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea Versicolor
-
Kasr El Aini HospitalRecruiting
-
Universitas PadjadjaranCompletedPityriasis VersicolorIndonesia
-
Taro Pharmaceuticals USACompletedTinea VersicolorUnited States
-
DermBiont, Inc.CompletedTinea VersicolorEl Salvador
-
Kasr El Aini HospitalRecruiting
-
The University of The West IndiesNot yet recruitingTinea VersicolorJamaica
-
Indonesia UniversityCompleted
-
Sara BotrosCompleted
-
Boni Elewski, MDCompleted
-
Combined Military Hospital AbbottabadCompleted
Clinical Trials on itraconazole gel once daily
-
Mimetica Pty LimitedCompleted
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Kowa Company, Ltd.Recruiting
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Russian Federation, Chile, South Africa, Romania, Slovakia
-
Inflazyme Pharmaceuticals LtdCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
PfizerTerminatedParkinson DiseaseUnited States, France, Israel, Germany
-
Spectrum Pharmaceuticals, IncTerminated